Compare Illumina, Inc. (ILMN) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Kinder Morgan Inc — how do they compare? Illumina, Inc. trades at $270.52 (market cap $39.95B), while Kinder Morgan Inc trades at $32.38 (market cap $71.81B). The key difference: Kinder Morgan Inc is the larger of the two by market cap, and Kinder Morgan Inc pays a 3.66% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Kinder Morgan Inc for 150 Days on average.
| ILMN | KMI | |
|---|---|---|
Market Cap | $39.95B | $71.81B |
Volume | 3,169,503 | 16,921,908 |
Sector | Health | Energy |
52-Week High | $293.69 | $34.31 |
52-Week Low | $91.00 | $25.84 |
Typical Hold Time | 83 Days | 150 Days |
Enterprise Value | $41.31B | $103.86B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Kinder Morgan (KMI) trades at $32.36, up 1.7% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and consistent earnings beats, while maintaining a 19.31% net income margin. Recent news highlights the company's $6B-$7B growth pipeline and resilience in volatile energy markets.
KMI presents a compelling investment case with analyst consensus target of $37.20 (15% upside), strong dividend yield, and fee-based revenue model. Key risks include energy market volatility and high debt levels, but the company's project backlog and natural gas demand growth support positive long-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
